Test tube gut and liver alternative to animal testing
A group of Scottish scientists are developing a new way to test the toxicity of nanoparticles
The three-year, £2m, InLiveTox project brings together leaders in nanotoxicology from around the world, including Edinburgh Napier University, to develop a way of testing the toxicity of ingested nanoparticles that does not rely on animals. Instead, a test-tube gut and liver will emulate the response of cells and tissues to ingestion of the tiny particles.
Nanotechnology promises new materials with enhanced properties that perform a variety of roles, including cancer treatment in drugs, stain resistance in clothes and preservatives in food. While there are clear benefits, concerns remain about their safe use.
Dr Gary Hutchison, acting director of Edinburgh Napier’s Centre for Nano Safety, said: ‘Given the widespread use of nanomaterials in variety of everyday products, it is essential for us fully to understand them and their potential impact. We are working with other European specialists on the InLiveTox project to develop a viable, effective alternative to using animals in such testing.
‘A recent change in European chemical safety legislation means that there is a requirement for information on the toxicity of all materials used in significant quantities by 2018. This means there is pressure to investigate thoroughly how substances affect humans in the long term. Animal testing has long been a way of establishing this but it is highly controversial. It is estimated that 3.9 million animals may be needed to adhere to the regulations. Ideally we want to play a part in reducing that number.’
The Centre for Nano Safety is part of Edinburgh Napier University’s Institute for Science & Health Innovation. Its toxicologists work with industry towards the safe use and understanding of the impact of nanomaterials in a variety of everyday products.
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Read moreTwo life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Trending Articles
Upcoming event
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development
Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder
The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development
Researchers identify early signs of Parkinson's in the blood
Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Research & Development
iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases
The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development